Stem Cell Contribution to Management of Cardiomyopathy
Cardiomyopathy is a cardiac condition where the heart’s muscle deteriorates and loses its ability to pump blood efficiently, which leads to heart failure. This condition is commonly the end-stage of coronary vessel disease but it can also be caused by other conditions, including family history, alcohol consumption and various infections and metabolic disorders, or it may be idiopathic- without known cause. While there is no cure for heart failure short of transplantation, stem cell therapy for cardiomyopathy provided by Gulf Coast Stem Cell & RMC as part of investigational protocols may help the heart muscles recover some function through regenerative growth and recruitment.
Those with cardiomyopathy may not experience any symptoms at the early onset of the condition since that is often insidious. However, as it advances, symptoms will likely begin to appear and often include breathlessness, tiredness, fatigue, swelling of the ankles, bloating, coughing, irregular heartbeats, dizziness, lightheadedness, and fainting.
Cardiomyopathy, can be diagnosed by physical examination, supplemented by blood tests, a chest X-ray, an echocardiogram, and an electrocardiogram (ECG). There may be a need for cardiac catheterization.
Stem cells derived from various sources have been show by animal and human research to help the heart muscle recover some function. Adipose mesenchymal (fatty tissue) stem cells are ideally suited for use in those high risk patients, because of the exceedingly low risk the procurement and deployment carrie. Stem cells can either be deployed intravenously, placed in the coronary arteries or in the heart’s coronary sinus by catheterization. However, experience has shown that the intravenous route is the safest, simplest, safest and cheapest since it involves no hospitalization or expensive machinery, and yields clinically positive results, almost as good.
Visit the Gulf Coast Stem Cell & RMC in Ocean Springs, MI to learn more about joining our investigational stem cell therapy studies for cardiomyopathy.